中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 40 Issue 11
Nov.  2024
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2024  >  40(11): 2183-2190

Interpretation of REDISCOVER international guidelines on the perioperative care of surgical patients with borderline-resectable and locally advanced pancreatic cancer （2024）

DOI: 10.12449/JCH241110
  • a.

    Department of Hepatobiliary Surgery，The First Affiliated Hospital of Xi’an Jiaotong University，Xi’an 710061，China

  • b.

    Pancreatic Diagnosis and Treatment Center，The First Affiliated Hospital of Xi’an Jiaotong University，Xi’an 710061，China

Research funding:

National Natural Science Foundation of China (82172853)

More Information
  • Corresponding author: HAN Liang， hanliangxjtu@163.com （ORCID： 0000-0002-3268-5214）
  • Received Date: 2024-08-29
  • Accepted Date: 2024-09-25
  • Published Date: 2024-11-25
    Abstract
  • The REDISCOVER international guidelines on the perioperative care of surgical patients with borderline-resectable and locally advanced pancreatic cancer were released in July 2024， and based on the existing clinical challenges， the guidelines provide important recommendations for the diagnosis， staging， and surgical treatment of borderline-resectable and locally advanced pancreatic cancer from an evidence-based perspective. This article gives an interpretation of the guidelines， in order to better guide clinical practice.

     

    • FullText(HTML)
  • loading
    • References(51)
  • [1]
    SIEGEL RL, MILLER KD, FUCHS HE, et al. Cancer Statistics, 2021[J]. CA Cancer J Clin, 2021, 71( 1): 7- 33. DOI: 10.3322/caac.21654.
    [2]
    SESHACHARYULU P, BAINE MJ, SOUCHEK JJ, et al. Biological determinants of radioresistance and their remediation in pancreatic cancer[J]. Biochim Biophys Acta Rev Cancer, 2017, 1868( 1): 69- 92. DOI: 10.1016/j.bbcan.2017.02.003.
    [3]
    BEAR AS, VONDERHEIDE RH, O’HARA MH. Challenges and opportunities for pancreatic cancer immunotherapy[J]. Cancer Cell, 2020, 38( 6): 788- 802. DOI: 10.1016/j.ccell.2020.08.004.
    [4]
    KATHER JN, HEIJ LR, GRABSCH HI, et al. Pan-cancer image-based detection of clinically actionable genetic alterations[J]. Nat Cancer, 2020, 1( 8): 789- 799. DOI: 10.1038/s43018-020-0087-6.
    [5]
    National Comprehensive Cancer Network. NCCN guidelines for pancreatic adenocarcinoma(Version 2. 2023)[EB/OL].( 2023-10-22). https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf. https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf
    [6]
    BOGGI U, DEL CHIARO M, CROCE C, et al. Prognostic implications of tumor invasion or adhesion to peripancreatic vessels in resected pancreatic cancer[J]. Surgery, 2009, 146( 5): 869- 881. DOI: 10.1016/j.surg.2009.04.029.
    [7]
    ISAJI S, MIZUNO S, WINDSOR JA, et al. International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017[J]. Pancreatology, 2018, 18( 1): 2- 11. DOI: 10.1016/j.pan.2017.11.011.
    [8]
    OBA A, CROCE C, HOSOKAWA P, et al. Prognosis based definition of resectability in pancreatic cancer: A road map to new guidelines[J]. Ann Surg, 2022, 275( 1): 175- 181. DOI: 10.1097/SLA.0000000000003859.
    [9]
    MAGGINO L, MALLEO G, MARCHEGIANI G, et al. Outcomes of primary chemotherapy for borderline resectable and locally advanced pancreatic ductal adenocarcinoma[J]. JAMA Surg, 2019, 154( 10): 932- 942. DOI: 10.1001/jamasurg.2019.2277.
    [10]
    CONROY T, PFEIFFER P, VILGRAIN V, et al. Pancreatic cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up[J]. Ann Oncol, 2023, 34( 11): 987- 1002. DOI: 10.1016/j.annonc.2023.08.009.
    [11]
    LOOS M, MACK CE, XU ATL, et al. Distal pancreatectomy: Extent of resection determines surgical risk categories[J]. Ann Surg, 2024, 279( 3): 479- 485. DOI: 10.1097/SLA.0000000000005935.
    [12]
    LOOS M, AL-SAEEDI M, HINZ U, et al. Categorization of differing types of total pancreatectomy[J]. JAMA Surg, 2022, 157( 2): 120- 128. DOI: 10.1001/jamasurg.2021.5834.
    [13]
    BOGGI U, KAUFFMANN E, NAPOLI N, et al. REDISCOVER international guidelines on the perioperative care of surgical patients with borderline-resectable and locally advanced pancreatic cancer[J]. Ann Surg, 2024, 280( 1): 56- 65. DOI: 10.1097/SLA.0000000000006248.
    [14]
    BOCKHORN M, UZUNOGLU FG, ADHAM M, et al. Borderline resectable pancreatic cancer: A consensus statement by the International Study Group of Pancreatic Surgery(ISGPS)[J]. Surgery, 2014, 155( 6): 977- 988. DOI: 10.1016/j.surg.2014.02.001.
    [15]
    Scottish Intercollegiate Guidelines Network(SIGN). A guideline developer’s handbook[EB/OL].[ 2024-08-29]. https://www.sign.ac.uk/media/2038/sign50_2019.pdf. https://www.sign.ac.uk/media/2038/sign50_2019.pdf
    [16]
    Grading Tutorial[EB/OL].[ 2024-08-29]. https://www.uptodate.com/home/gradingtutorial. https://www.uptodate.com/home/gradingtutorial
    [17]
    BROUWERS MC, KHO ME, BROWMAN GP, et al. AGREE II: Advancing guideline development, reporting and evaluation in health care[J]. J Clin Epidemiol, 2010, 63( 12): 1308- 1311. DOI: 10.1016/j.jclinepi.2010.07.001.
    [18]
    J EJ, LINSTONE HA, TUROFF M. The Delphi method: Techniques and applications[J]. Technometrics, 1976, 18( 3): 363. DOI: 10.2307/1268751.
    [19]
    AJINA R, WEINER LM. T-cell immunity in pancreatic cancer[J]. Pancreas, 2020, 49( 8): 1014- 1023. DOI: 10.1097/MPA.0000000000001621.
    [20]
    NAPOLI N, KAUFFMANN EF, LOMBARDO C, et al. Postoperative results, learning curve, and outcomes of pancreatectomy with arterial resection: A single-center retrospective cohort study on 236 procedures[J]. Int J Surg, 2023, 110( 10): 6111- 6125. DOI: 10.1097/JS9.0000000000000971.
    [21]
    HE JX, LV N, YANG ZY, et al. Comparing upfront surgery with neoadjuvant treatments in patients with resectable, borderline resectable or locally advanced pancreatic cancer: A systematic review and network meta-analysis of randomized clinical trials[J]. Int J Surg, 2024, 110( 6): 3900- 3909. DOI: 10.1097/JS9.0000000000001313.
    [22]
    BOGGI U. Resection for pancreatic cancer with arterial involvement: A paradigm shift away from unresectable to“how to do it”[J]. Surgery, 2021, 169( 5): 1036. DOI: 10.1016/j.surg.2020.10.047.
    [23]
    REAMES BN, BLAIR AB, KRELL RW, et al. Management of locally advanced pancreatic cancer: Results of an international survey of current practice[J]. Ann Surg, 2021, 273( 6): 1173- 1181. DOI: 10.1097/SLA.0000000000003568.
    [24]
    National Comprehensive Cancer Network. NCCN guidelines for pancreatic adenocarcinoma. Version 1.2024[EB/OL].( 2024-02-10). https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf. https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf
    [25]
    SEELEN LWF, DOPPENBERG D, STOOP TF, et al. Minimum and optimal CA19-9 response after two months induction chemotherapy in patients with locally advanced pancreatic cancer: A nationwide multicenter study[J]. Ann Surg, 2024, 279( 5): 832- 841. DOI: 10.1097/SLA.0000000000006021.
    [26]
    REN L, JÄGER C, SCHORN S, et al. Arterial resection for pancreatic cancer: Feasibility and current standing in a high-volume center[J]. Ann Surg Open, 2023, 4( 3): e302. DOI: 10.1097/AS9.0000000000000302.
    [27]
    STOOP TF, MACKAY TM, BRADA LJH, et al. Pancreatectomy with arterial resection for periampullary cancer: Outcomes after planned or unplanned events in a nationwide, multicentre cohort[J]. Br J Surg, 2023, 110( 6): 638- 642. DOI: 10.1093/bjs/znac353.
    [28]
    FROMER MW, HAWTHORNE J, PHILIPS P, et al. An improved staging system for locally advanced pancreatic cancer: A critical need in the multidisciplinary era[J]. Ann Surg Oncol, 2021, 28( 11): 6201- 6210. DOI: 10.1245/s10434-021-10174-z.
    [29]
    BACHELLIER P, ROSSO E, FUCHSHUBER P, et al. Use of a temporary intraoperative mesentericoportal shunt for pancreatic resection for locally advanced pancreatic cancer with portal vein occlusion and portal hypertension[J]. Surgery, 2014, 155( 3): 449- 456. DOI: 10.1016/j.surg.2013.09.003.
    [30]
    BOGGI U, NAPOLI N, KAUFFMANN EF, et al. Pancreatectomy with resection and reconstruction of the superior mesenteric artery[J]. Br J Surg, 2023, 110( 8): 901- 904. DOI: 10.1093/bjs/znac363.
    [31]
    RATNAYAKE B, PENDHARKAR SA, CONNOR S, et al. Patient volume and clinical outcome after pancreatic cancer resection: A contemporary systematic review and meta-analysis[J]. Surgery, 2022, 172( 1): 273- 283. DOI: 10.1016/j.surg.2021.11.029.
    [32]
    KRAUTZ C, NIMPTSCH U, WEBER GF, et al. Effect of hospital volume on in-hospital morbidity and mortality following pancreatic surgery in Germany[J]. Ann Surg, 2018, 267( 3): 411- 417. DOI: 10.1097/SLA.0000000000002248.
    [33]
    VIVIAN E, BROOKS MR, LONGORIA R, et al. Improving the standard of care for all-a practical guide to developing a center of excellence[J]. Healthcare(Basel), 2021, 9( 6): 777. DOI: 10.3390/healthcare9060777.
    [34]
    GERO D, MULLER X, STAIGER RD, et al. How to establish benchmarks for surgical outcomes? A checklist based on an international expert Delphi consensus[J]. Ann Surg, 2022, 275( 1): 115- 120. DOI: 10.1097/SLA.0000000000003931.
    [35]
    FARGES O, BENDERSKY N, TRUANT S, et al. The theory and practice of pancreatic surgery in France[J]. Ann Surg, 2017, 266( 5): 797- 804. DOI: 10.1097/SLA.0000000000002399.
    [36]
    FARNES I, KLEIVE D, VERBEKE CS, et al. Resection rates and intention-to-treat outcomes in borderline and locally advanced pancreatic cancer: Real-world data from a population-based, prospective cohort study(NORPACT-2)[J]. BJS Open, 2023, 7( 6): zrad137. DOI: 10.1093/bjsopen/zrad137.
    [37]
    VONLANTHEN R, LODGE P, BARKUN JS, et al. Toward a consensus on centralization in surgery[J]. Ann Surg, 2018, 268( 5): 712- 724. DOI: 10.1097/SLA.0000000000002965.
    [38]
    NAPOLI N, KAUFFMANN E, CACACE C, et al. Factors predicting survival in patients with locally advanced pancreatic cancer undergoing pancreatectomy with arterial resection[J]. Updates Surg, 2021, 73( 1): 233- 249. DOI: 10.1007/s13304-020-00883-7.
    [39]
    DIENER MK, MIHALJEVIC AL, STROBEL O, et al. Periarterial divestment in pancreatic cancer surgery[J]. Surgery, 2021, 169( 5): 1019- 1025. DOI: 10.1016/j.surg.2020.08.030.
    [40]
    NELSON DW, BLANCHARD TH, CAUSEY MW, et al. Examining the accuracy and clinical usefulness of intraoperative frozen section analysis in the management of pancreatic lesions[J]. Am J Surg, 2013, 205( 5): 613- 617. DOI: 10.1016/j.amjsurg.2013.01.015.
    [41]
    BOGGI U, KAUFFMANN EF, NAPOLI N, et al. REDISCOVER guidelines for borderline-resectable and locally advanced pancreatic cancer: Management algorithm, unanswered questions, and future perspectives[J]. Updates Surg, 2024, 76( 5): 1573- 1591. DOI: 10.1007/s13304-024-01860-0.
    [42]
    HEGER U, SUN HH, HINZ U, et al. Induction chemotherapy in pancreatic cancer: CA 19-9 may predict resectability and survival[J]. HPB(Oxford), 2020, 22( 2): 224- 232. DOI: 10.1016/j.hpb.2019.06.012.
    [43]
    NEWHOOK TE, VREELAND TJ, GRIFFIN JF, et al. Prognosis associated with CA19-9 response dynamics and normalization during neoadjuvant therapy in resected pancreatic adenocarcinoma[J]. Ann Surg, 2023, 277( 3): 484- 490. DOI: 10.1097/SLA.0000000000005184.
    [44]
    TSAI S, GEORGE B, WITTMANN D, et al. Importance of normalization of CA19-9 levels following neoadjuvant therapy in patients with localized pancreatic cancer[J]. Ann Surg, 2020, 271( 4): 740- 747. DOI: 10.1097/SLA.0000000000003049.
    [45]
    van ROESSEL S, van VELDHUISEN E, KLOMPMAKER S, et al. Evaluation of adjuvant chemotherapy in patients with resected pancreatic cancer after neoadjuvant FOLFIRINOX treatment[J]. JAMA Oncol, 2020, 6( 11): 1733- 1740. DOI: 10.1001/jamaoncol.2020.3537.
    [46]
    MA M, NIU TT, HAO Q, et al. Clinical effect analysis of stereotactic radiotherapy combined with concurrent chemoradiotherapy in the treatment of pancreatic cancer[J]. Trauma Crit Care Med, 2022, 10( 5): 380- 381. DOI: 10.16048/j.issn.2095-5561.2022.05.18.

    马明, 牛婷婷, 郝倩, 等. 立体定向放射治疗联合同步放化疗治疗胰腺癌临床效果分析[J]. 创伤与急危重病医学, 2022, 10( 5): 380- 381. DOI: 10.16048/j.issn.2095-5561.2022.05.18.
    [47]
    WANG CY, LIU XH, WANG XH, et al. Effects of chemoradiotherapy and chemotherapy on survival of patients with locally advanced pancreatic cancer: A meta-analysis of randomized controlled trials[J]. Medicine(Baltimore), 2018, 97( 36): e12260. DOI: 10.1097/MD.0000000000012260.
    [48]
    HOMMA Y, ENDO I, MATSUYAMA R, et al. Outcomes of lung metastasis from pancreatic cancer: A nationwide multicenter analysis[J]. J Hepatobiliary Pancreat Sci, 2022, 29( 5): 552- 561. DOI: 10.1002/jhbp.1127.
    [49]
    HASHIMOTO D, SATOI S, FUJII T, et al. Is surgical resection justified for pancreatic ductal adenocarcinoma with distant abdominal organ metastasis? A position paper by experts in pancreatic surgery at the Joint Meeting of the International Association of Pancreatology(IAP)& the Japan Pancreas Society(JPS) 2022 in Kyoto[J]. Pancreatology, 2023, 23( 6): 682- 688. DOI: 10.1016/j.pan.2023.07.005.
    [50]
    GIANNONE F, CAPRETTI G, HILAL M ABU, et al. Resectability of pancreatic cancer is in the eye of the observer: A multicenter, blinded, prospective assessment of interobserver agreement on NCCN resectability status criteria[J]. Ann Surg Open, 2021, 2( 3): e087. DOI: 10.1097/AS9.0000000000000087.
    [51]
    GODHI SA, PARASAR K, SALUJA S, et al. Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer[J]. Ann Surg, 2017, 265( 6): E73. DOI: 10.1097/SLA.0000000000001322.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(2)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (123) PDF downloads(26) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return